The U.S. Food and Drug Administration said on Monday that it had launched a generative AI tool, Elsa, aimed at improving efficiency across its operations, including scientific reviews.
“Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers,” said FDA Commissioner Marty Makary.
The agency said it is already using Elsa to expedite clinical protocol reviews, shorten the time needed for scientific evaluations, and pinpoint high-priority inspection targets.
Once the FDA receives an application for a potential drug approval, it has six to 10 months to make a decision.
Elsa assists with reading, writing, and summarizing tasks. It can summarize adverse events to support safety profile assessments of drugs and rapidly compare packaging inserts.
“Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff,” the FDA said.
In May, the regulator said it would fully integrate AI by June 30, following an experimental run.
—Puyaan Singh, Reuters
Jelentkezéshez jelentkezzen be
EGYÉB POSTS Ebben a csoportban
Cheap or free access to AI models keeps improving, with Google the latest firm to make its newest models availabl
Amazon is gearing up to make as many as 10,000 robotaxis annually at a sprawling plant n
The world’s three best-selling makers of bitcoin mining machines—all of Chinese origin—are
It’s been almost 400 years since the leaders of New Amsterdam (now New York City) confronted a growing threat on their streets: people moving too fast. In 1652, the colonial council passed what ma
President Donald Trump will sign an executive order this week to
The Backrooms started as internet folklore posted on 4Chan. Now it’s been greenlit by A24.
Last week, it was announced that 19-year-old YouTuber Kane Parsons will direct the sci-fi/horro
